NDAORALTABLET
Approved
May 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PMB 200 is an oral combination tablet containing conjugated estrogens and meprobamate, a sedative-hypnotic anxiolytic. This product was developed for menopausal women experiencing vasomotor symptoms and anxiety, combining hormone replacement with anxiolytic therapy in a single fixed-dose formulation.
LOE Approaching
Product is approaching loss of exclusivity with minimal current commercial activity; limited career growth opportunities and likely small, focused team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PMB 200 offers minimal career growth; this is a legacy maintenance role suited for professionals managing product wind-down or niche specialty markets. Career development is constrained by the product's approaching loss of exclusivity, minimal commercial investment, and absence of clinical development.
Product Manager (Legacy/Specialty)Regulatory Affairs (Compliance & Maintenance)
Worked on PMB 200 at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.